Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

NCT02870231 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolism and Nutrition Disorder
Obesity

Interventions

DRUG: NNC9204-0530
DRUG: liraglutide
DRUG: placebo

Sponsor

Novo Nordisk A/S